Today’s guest sits at the intersection of cutting-edge science and bold entrepreneurship. Dr. Lan Huang is the Co-Founder, CEO, and Chairman of SEED Therapeutics, where she’s leading the charge in developing next-generation medicines through targeted protein degradation—an approach that’s redefining what’s possible in drug discovery.

But she didn’t stop at the lab bench. Lan is also a seasoned biotech entrepreneur, having founded multiple companies across the U.S. and China, including BeyondSpring, which she led to a successful public listing. Across more than 15 years in the industry, she’s built a reputation for translating complex science into real-world treatments.

In this episode, we explore her journey from researcher to CEO, the promise of molecular glue therapies, and what it takes to build a biotech company at the frontier of innovation.

In this episode of The BioHub Podcast, Amber sits down with Nazli Azimi, Co-founder and CEO of Therna Biosciences.

Nazli has previously founded and scaled two biotech companies through to acquisition, and is now focused on building AI-driven platforms to design programmable RNA medicines.

In this conversation, we explore why many first-generation AI drug discovery companies struggled, and why grounding models in real biological questions and high-quality data is critical.

We also discuss what it means to “program” RNA medicines, from designing molecules with specific properties to controlling gene expression at the transcript level.

Nazli shares a real-world example of designing an RNA molecule for a pulmonary fibrosis patient in a matter of days, and what this could mean for the future of personalised therapies.

Where AI in drug discovery starts to move beyond hype and into reality.

On this episode we meet Sam Possemiers, CEO at MRM Health, the leading developers of microbiome-based therapeutics within IBD.

We discuss the origins of their CORAL platform, which was brought to life in the basement of Ghent University by Willy Verstraete. The concept of "Microbial Resource Management" and how Sam used the profits from his successful CRO, ProDigest, to self-fund the seed and go all-in on MRM.

Sam & the team's latest milestones include ph2b STARFISH-UC trial initiation, & an upcoming study in Pouchitis.

We also close on what it took to raise their €55million Series B, which Sam closed whilst literally halfway up an Alp, and the learnings Sam has taken from that process.

In this episode of The BioHub Podcast, Max sits down with Dr. Atta Behfar, Co-Founder of Rion and Professor of Regenerative Medicine at Mayo Clinic.

Atta’s work at Mayo led to a key discovery that became the foundation for Rion, a clinical-stage company developing exosome-based therapeutics through its Purified Exosome Product (PEP) platform.

In this conversation, Atta shares the story behind that discovery, how it translated into a company, and the potential of cell-free regenerative medicine to make advanced biologics more accessible to patients.

We also discuss Rion’s progress in wound healing, how the team has been built, and what’s next for their pipeline.

A fascinating look at how breakthrough science becomes real therapies.

In this episode of The BioHub Podcast, Max sits down with Srinivas Rao, CEO of atai Beckley.

Srini has been there from the very beginning, helping build atai into one of the leading companies in the mental health and psychedelics space, and now leading the next chapter following the merger with Beckley.

In this conversation, we talk about how atai was founded, the evolution of the psychedelics space, and what it takes to build in one of the most challenging and closely watched areas in biotech.

We also discuss Srini’s transition into the CEO role, the strategy behind the merger, and what’s coming next for the company.

We were delighted to welcome Daniel Fero, Managing Director of OMX Ventures, onto the Biohub. He's working at the intersection of science, startups, and investment — where breakthrough research meets real-world impact.

Daniel Fero is a venture investor focused on biotech and life sciences, with experience spanning early-stage company building and healthcare innovation. Based in the Greater Boston area — one of the world’s leading hubs for biomedical research — Daniel works closely with scientists and founders to help translate cutting-edge discoveries into companies that can reshape how we understand and treat disease.

He’s particularly engaged in the world of biotech venture capital, where deep scientific insight meets high-stakes decision-making about which ideas are worth backing, scaling, and bringing to market. His work touches everything from university spinouts to emerging therapeutics, reflecting a broader mission: accelerating the path from lab bench to patient impact.

In this conversation, we’ll explore Daniel’s journey into venture investing, what he looks for in early-stage biotech companies, and how innovation is evolving at the frontier of healthcare and life sciences.

In todays episode we talk about Dan's career and the work Pelage are doing, leading innovation in the hair loss space.

In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.

Jeremy’s career spans roles at Genentech, Opsona, and Inflazome, which was acquired by Roche before stepping into the CEO role at Poolbeg, a public biotech taking a different approach to drug development.

In this conversation, we talk about how Poolbeg is building a more capital-efficient, data-driven model, the realities of today’s biotech market, and how companies can position themselves to succeed in a tougher funding environment.

It’s a great in-person discussion on what it really takes to build differently in biotech today.

Today’s guest is Ashley Zehnder, the co-founder and CEO of Fauna Bio—a pioneering biotech company unlocking insights from the natural world to transform human health.

With a background in genomics and a passion for translating cutting-edge science into real-world therapies, Ashley is leading a new frontier in drug discovery—one that looks to nature’s own evolutionary experiments to uncover novel treatments for disease.

Under her leadership, Fauna Bio is redefining how we approach medicine by combining comparative biology, machine learning, and massive genomic datasets to identify breakthroughs that traditional methods might miss.

In this episode, we’ll explore Ashley’s journey from scientist to CEO, the bold vision behind Fauna Bio, and how studying the biology of extraordinary animals could reshape the future of healthcare.

In this episode of The BioHub Podcast, Max sits down with Robert Jacks, President and CEO of Sparrow Pharmaceuticals.

Robert brings more than 25 years of experience in biotech, having founded or co-founded multiple companies and raised over $300 million across his career. From roles in corporate development at Pfizer to leading companies through development, approval, and exit, he’s seen the industry from every angle.

In this conversation, Robert shares his journey into biotech leadership, the story behind Sparrow, and what it takes to build and scale companies while staying lean and focused.

They also discuss raising capital in today’s market, navigating the challenges of biotech, and where the industry is heading next.